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Introduction 
Joint disorders are responsible of reduced quality of life and high socio-economic burden in our 
progressively ageing and physically active population. Even though huge efforts on the development of 
cartilage repair strategies, presently no approach has demonstrate full efficiency. The present study aimed 
to create an innovative advanced-therapy medicinal product (ATMP) where human adipose-derived 
stem/stromal cells (hASCs) 1 encapsulated within a novel hydrogel based on methacrylated gellan gum 
(mimsys G) 2 will develop cartilage-like tissue. These complete xeno-free 3D approach was developed and 
in vitro experiment were conducted under static and dynamic conditions, the latest using a rotational dual 
chamber bioreactor 3. Preliminary in vivo assay using rabbit model of cartilage defect was based on 
autologous and allogenic approaches. Both in vitro and in vivo experiments were established to evaluate 
the performance of this system on focal cartilage tissue engineering. 
 
Materials and Methods 
Human ASC (hASC xeno-free, irisbiosciences), isolated in GMP conditions, were expanded in xeno-free 
media until sub-confluency. mimsys G hydrogel (mimsys®G, irisbiosciences) was prepared to yield a 2% 
w/V solution. Cells were encapsulated at 10x106 cells/mL, ionically crosslinked and cultured with or 
without chondrogenic induction for 21 days. For dynamic growth, a rotational dual chamber bioreactor 
was used to control the perfusion and flow gradient within the cellular scaffolds. Cell viability was 
determined by live/dead assay, and cell metabolic activity by MTS reduction. A in vivo study evaluated 
regeneration of focal cartilage lesions on a rabbit knee model for 8 weeks, using autologous and allogenic 
approaches. Rabbit ASCs (rASCs), isolated from fat pad, and hASCs were encapsulated into mimsys G 
prior administration into the cartilage defect. Chondrogenesis was assessed on both in vitro and in vivo 
samples by histological staining of cartilage matrix using safranin O and immunolocalization of collagen 
type II. Expression of chondrogenic-related genes (aggrecan, collagen type II and sox-9) were also 
determined.   
 
Results 
In vitro analysis of the new ATMP demonstrated high viability of the cells and progressive metabolic 
activity along static and dynamic culture. Additionally, intense cartilage matrix deposition was detected 
through up-regulation of chondrogenic maker Collagen II gene and protein (Immunohistochemistry) by 
end of culture (Fig.1). For the in vivo study, both autologous and allogenic approaches demonstrated the 
establishment of lateral and subchondral integration (Fig.2).  
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Fig.1. In vitro Chondrogenesis – Collagen II gene (A) and protein (B) expression at day 0 and day 21, 
after chondrogenic induction in static culture conditions. Fig 2. In vivo study – Safranin-O staining after 
regeneration of cartilage lesion. 
 
Discussion and Conclusions 
The proposed innovative ATMP demonstrated intense cartilage development in vitro through evaluation 
of specific markers. Preliminary in vivo data demonstrates promising repair performance in focal cartilage 
lesions, suggesting a valuable approach for further therapeutic exploitation.     
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